Aspira Women's Health Q4 product revenue up 9.5% to $2.3M; FY revenue flat at $9.2M

Aspira Women's Health Inc.

Q4 product revenue $2.3M (+9.5% YoY); OvaSuite tests ~6,004 (+6.1%); AUP $391 (+4.3%); gross margin 63.4% (+6.2 ppts).
FY product revenue $9.2M (flat YoY); tests ~24,305 (+1.3%); AUP $378 (-1.0%); gross margin 59.7% (+2.2 ppts).
Operating expenses Q4 $4.9M (-8% YoY); FY $21.8M (-10% YoY).
Cash ~$3.7M as of Mar 27, 2025; pending $1.5M ARPA-H milestone; raised $5.75M via convertible notes and ATM.
New CEO Mike Buhle appointed; ARPA-H $10M award milestone; Ellen Beausang added to Board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.